BRPI0812322A2 - Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica - Google Patents

Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica

Info

Publication number
BRPI0812322A2
BRPI0812322A2 BRPI0812322-5A2A BRPI0812322A BRPI0812322A2 BR PI0812322 A2 BRPI0812322 A2 BR PI0812322A2 BR PI0812322 A BRPI0812322 A BR PI0812322A BR PI0812322 A2 BRPI0812322 A2 BR PI0812322A2
Authority
BR
Brazil
Prior art keywords
neutrotoxic
thermostable
provision
component
muscle relaxant
Prior art date
Application number
BRPI0812322-5A2A
Other languages
English (en)
Inventor
Karl Heinz Eisele
Matthias Marx
Harold V Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0812322A2 publication Critical patent/BRPI0812322A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0812322-5A2A 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica BRPI0812322A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
PCT/EP2008/004254 WO2008145359A1 (en) 2007-06-01 2008-05-28 Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin

Publications (1)

Publication Number Publication Date
BRPI0812322A2 true BRPI0812322A2 (pt) 2014-11-25

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0812245-8A2A BRPI0812245A2 (pt) 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica na forma sólida
BRPI0812322-5A2A BRPI0812322A2 (pt) 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0812245-8A2A BRPI0812245A2 (pt) 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica na forma sólida

Country Status (15)

Country Link
US (2) US20090028906A1 (pt)
EP (2) EP2170375A1 (pt)
JP (2) JP2010528999A (pt)
KR (2) KR20100020972A (pt)
CN (2) CN101720331A (pt)
AR (2) AR066782A1 (pt)
AU (2) AU2008256418A1 (pt)
BR (2) BRPI0812245A2 (pt)
CA (2) CA2686637A1 (pt)
IL (2) IL202129A0 (pt)
MX (2) MX2009012990A (pt)
RU (1) RU2009149604A (pt)
TW (2) TW200914039A (pt)
WO (2) WO2008145358A1 (pt)
ZA (2) ZA200907875B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
KR102005930B1 (ko) 2008-12-31 2019-07-31 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
KR101806567B1 (ko) * 2009-02-19 2018-01-10 메르츠 파마 게엠베하 운트 코. 카가아 매우 순수한 신경독을 제조하기 위한 수단 및 방법
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8663942B2 (en) * 2009-04-27 2014-03-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
KR20210141783A (ko) 2009-06-25 2021-11-23 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
MX365496B (es) * 2009-10-21 2019-06-05 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
BR112013025256B1 (pt) * 2011-03-31 2022-01-18 Medy-Tox Inc Preparação liofilizada farmacêutica
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
CA2971238C (en) 2014-12-23 2022-12-13 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
CN107206175B (zh) 2015-02-03 2021-06-01 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
WO2023186016A1 (zh) * 2022-04-01 2023-10-05 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物、制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20030224020A1 (en) * 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
JP4907530B2 (ja) * 2004-07-26 2012-03-28 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン ボツリヌス神経毒を含む治療用組成物
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
PL1891200T3 (pl) * 2005-06-17 2009-10-30 Merz Pharma Gmbh & Co Kgaa Urządzenie i sposób do fermentacyjnego wytwarzania biologicznie aktywnych materiałów
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
AR066782A1 (es) 2009-09-09
AU2008256419A1 (en) 2008-12-04
CA2686642A1 (en) 2008-12-04
CN101720331A (zh) 2010-06-02
ZA200907875B (en) 2010-11-24
AU2008256418A1 (en) 2008-12-04
MX2009012570A (es) 2010-03-15
WO2008145358A1 (en) 2008-12-04
US20090028906A1 (en) 2009-01-29
CN101687018A (zh) 2010-03-31
JP2010528999A (ja) 2010-08-26
US20090010965A1 (en) 2009-01-08
BRPI0812245A2 (pt) 2014-10-21
TW200914039A (en) 2009-04-01
EP2164861A1 (en) 2010-03-24
KR20100020972A (ko) 2010-02-23
RU2009149604A (ru) 2011-07-20
JP2010529000A (ja) 2010-08-26
TW200902050A (en) 2009-01-16
WO2008145359A1 (en) 2008-12-04
KR20100020971A (ko) 2010-02-23
IL202129A0 (en) 2010-06-16
EP2170375A1 (en) 2010-04-07
AR066783A1 (es) 2009-09-09
MX2009012990A (es) 2010-04-01
IL202130A0 (en) 2010-06-16
CA2686637A1 (en) 2008-12-04
ZA200907874B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
BRPI0812322A2 (pt) Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica
BRPI0821729A2 (pt) Tapete, revestimento de tapete e método para fabricar um tapete
BRPI0811830A2 (pt) "composição de revestimento, método para revestir um substrato e substrato"
BRPI0819891A2 (pt) aparelho modular de poço para determinar uma propriedade da formação, e método para determinar um propriedade da formação
BRPI0817398A2 (pt) "método para fabricação de um dispositivo, dispositivo para inalação e dispositivo ou componente"
BRPI0920301A2 (pt) método para marcar um substrato oftálmico ou outro artigo oftálmico, e, aparelho
BRPI0807906A2 (pt) Token pessoal tendo habilidades de comunicação aperfeiçoadas para um aplicativo hospedado.
PT2034844T (pt) Método para o tratamento de síndrome do intestino irritável com predominância de diarreia
DK1982230T3 (da) Pseudo-akkomodativ iol med flere diffraktive mønstre
EP2024026A4 (en) NERVE COIFFE AND METHOD AND APPARATUS FOR MANUFACTURING THE SAME
FI20065404L (fi) Prosessi perusöljyn valmistamiseksi
DK2046831T3 (da) Hidtil ukendte, multivalente immunoglobuliner
BRPI0717412A2 (pt) Filme único, e, método para a produção de um filme único
EP2136626A4 (en) Mannich base n-oxide drugs
BRPI0916156A2 (pt) "folha não-tecida, componente de isolação elétrica para um dispositivo elétrico, isolação útil para um dispositivo elétrico e método para produzir folha não-tecida de fibra polimérica multicomponente"
EP2035398A4 (en) Immobilized 1,2-benzisothiazolin-3-one
BRPI0908689A2 (pt) 'método para formação de uma sinalização, sinalizações e métodos para formação de um artigo com imagem
DE602007010225D1 (de) Synchronisationsverfahren und -anordnung
AT506023A3 (de) Elastischer walzenüberzug, überzogene walze und verfahren zur herstellung einer überzogenen walze
BRPI0917952A2 (pt) método para fabricaar um componente de revestimento para um moinho, e, componente de revistimento para um moinho
BRPI0820612A2 (pt) Processo de combustão, e, emissões
BRPI0718200A2 (pt) aparelho para observar a aparência da superfície de uma amostra, e, método para observar a aparência da superfície de uma amostra
BRPI0813366A2 (pt) Método para executar uma combustão.
DE502007002958D1 (de) Armierte supraleitende wicklung und verfahren zu deren herstellung
EP1981964A4 (en) MYCOBACTERIAL SECA2 MUTANTS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 38/48 (2006.01)